NASDAQ$EXEL

Exelixis Inc · Q2 2022 earnings

Q2 2022 earnings · · Investor relations

Briefing

Exelixis reported strong commercial performance for CABOMETYX and advancements in pipeline activities.

Exelixis announced its second quarter 2022 financial results with total revenues of $419.4 million and GAAP diluted EPS of $0.22. The company highlighted the 22 percent growth in cabozantinib franchise net product revenues year-over-year and key cabozantinib milestones.

  • Total revenues for the quarter ended June 30, 2022 were $419.4 million.
  • GAAP net income for the quarter ended June 30, 2022 was $70.7 million, or $0.22 per share, basic and diluted.
  • Non-GAAP net income for the quarter ended June 30, 2022 was $89.7 million, or $0.28 per share, basic and diluted.
  • Cash, cash equivalents, restricted cash equivalents and investments were $2.0 billion at June 30, 2022.

Headline financials

Total Revenue

$419M

Previous: $385M+8.9%
EPS (adj)

$0.28

Previous: $0.37-24.3%
Research and Development Expenses

$199M

Previous: $149M+34.1%
Selling, General and Administrative Expenses

$123M

Previous: $98.5M+24.6%
Provision for Income Taxes

$17.8M

Previous: $28.8M-38.1%
Capital Expenditures

-$17.9M

Previous: -$33.8M+46.9%
Free Cash Flow

$52.7M

Previous: $62.3M-15.4%
Net Income

$70.7M

Previous: $96.1M-26.5%
Operating Income

$83.7M

Previous: $123M-32.0%
Gross Profit

$406M

Previous: $370M+9.6%
Cash & Equivalents

$627M

Previous: $1.74B-63.9%
Total Assets

$2.88B

Previous: $2.37B+21.7%
Stock-Based Comp

$24.6M

Previous: $28M-12.2%

Revenue & EPS history

Exelixis · Revenue · Quarterly

$419M

Q2 2022+8.9%vs Q2 2021
Beat estimate in 11 of 15 quarters(73%)
ActualEstimate

Revenue by segment

Exelixis · $405M total across 3 segments · Q2 2022

  • CABOMETYX Net Product Revenue
    $339M+23.1%
  • Collaboration Revenues
    $57.5M+45.1%
  • COMETRIQ Net Product Revenue
    $7.9M-8.1%

Forward guidance

Exelixis is maintaining the following previously provided financial guidance for fiscal year 2022:

Tailwinds

  • Total revenues $1.525 billion - $1.625 billion
  • Net product revenues $1.325 billion - $1.425 billion
  • Cost of goods sold 5% - 6% of net product revenues
  • Research and development expenses $725 million - $775 million
  • Selling, general and administrative expenses $400 million - $450 million

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2022

Historical avgQ2 2022

+0.5%

Avg return

Earnings day

+2.7%

Avg return

5 days after

+3.6%

Avg return

30 days after

48%

31 / 65 earnings

Positive

+25.5%

Q3 2018

Best reaction

-12.0%

Q4 2010

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+3.7%+11.9%+18.6%
Q4 2025-0.1%+2.2%-4.0%
Q3 2025+6.5%+9.3%+17.0%
Q1 2025+20.7%+20.9%+12.6%
Q4 2024-0.0%+6.7%+11.7%
Q3 2024+13.8%+19.7%+26.1%
Q2 2024+12.8%+14.7%+8.7%
Q1 2024-7.6%-7.7%-12.4%
Q4 2023-5.7%-5.5%+3.2%
Q3 2023-2.2%+1.2%+6.6%
Q2 2023+3.2%+2.8%+13.6%
Q1 2023+1.8%+0.8%+1.7%
Q4 2022+2.8%+1.6%-3.5%
Q3 2022+2.6%-0.7%+2.8%
Q2 2022-9.5%-9.6%-17.4%
Q1 2022+2.6%+3.8%-2.4%
Q4 2021+2.5%+2.7%+12.1%
Q3 2021-11.3%-10.8%-24.1%
Q2 2021+2.7%+2.5%+17.7%
Q1 2021+4.8%+3.0%-6.7%
Q4 2020-3.8%-4.5%+1.4%
Q3 2020-8.3%-6.0%-16.0%
Q2 2020-3.0%-6.0%-10.3%
Q1 2020+2.2%+1.4%-11.9%
Q4 2019-7.4%-7.9%-14.4%
Q3 2019-8.8%-5.0%-1.8%
Q2 2019-3.8%-6.7%-6.4%
Q1 2019+2.7%+5.0%-0.4%
Q4 2018+5.1%+6.1%+18.0%
Q3 2018+25.5%+22.3%+46.4%
Q2 2018+8.2%+1.2%-9.2%
Q1 2018+5.8%+5.8%-2.0%
Q4 2017-8.1%-18.4%-24.2%
Q3 2017+2.9%+10.4%+13.4%
Q2 2017-2.9%+0.8%+9.5%
Q1 2017+3.4%-3.2%-16.5%
Q4 2016-0.7%+6.4%-2.6%
Q3 2016+10.2%+15.4%+60.7%
Q2 2016+21.0%+19.5%+26.1%
Q1 2016+0.4%
Q4 2015-0.5%
Q3 2015-5.9%
Q2 2015-2.2%
Q1 2015+3.3%
Q4 2014-2.2%
Q3 2014+0.0%
Q2 2014-1.9%
Q1 2014-6.2%
Q4 2013-2.2%
Q3 2013-7.6%
Q2 2013-4.4%
Q1 2013+6.3%
Q4 2012-6.6%
Q3 2012-6.1%
Q2 2012-7.5%
Q1 2012-3.8%
Q1 2011-3.8%
Q4 2011+2.5%
Q4 2009+2.5%
Q3 2011+3.8%
Q3 2010+3.8%
Q2 2011-12.0%
Q4 2010-12.0%
Q2 2010-5.2%
Q1 2010+17.9%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro